Lenvatinib (off Label)
Lenvatinib MSK Phase 2
Eisai (investigator studies) · Phase 2 · Active, not recruiting · Enrollment 33
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Lenvatinib 24 mg | progressive R/M ACC (n = 32 evaluable) | 24 mg | Single arm | n/r | objective response rate: 15.6%, primary analysismedian progression-free survival: 17.5 months, 8 progression events |